Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1725-1730

  Krueger, W A ^a   Ruckdeschel, G ^b   Unertl, K ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; SUCRALFATE;

ADULT; AEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; CANDIDA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FECES LEVEL; ENTEROBACTERIACEAE; ENTEROCOCCUS; FATIGUE; FEMALE; FLATULENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE FLORA; INTRAVENOUS DRUG ADMINISTRATION; LACTOBACILLUS; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS; VERTIGO;

EID: 0030802464     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1725     Document Type: Article

References (39)

1. Bergan, T., C. Delin, S. Johansen, I. M. Kolstad, C. E. Nord, and S. B. Thorsteinsson. 1986. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob. Agents Chemother. 29:298-302.
2. Bergmans, D., M. Bonten, C. Gaillard, F. van Thiel, S. van der Geest, and E. Stobberingh. 1994. In vitro antibacterial activity of sucralfate. Eur. J. Clin. Microbiol. Infect. Dis. 13:615-620.
3. Brouwers, J. R. B., H. J. v. d. Kam, J. Sijtsma, and C. H. W. Koks. 1989. Important drug interaction of oral ciprofloxacin with sucralfate and magnesium citrate solution. Pharm. Weekbl. 11:13.
4. Brumfitt, W., I. Franklin, D. Grady, J. M. T. Hamilton-Miller, and A. Iliffe. 1984. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother. 26:757-761.
5. Daschner, F., I. Kappstein, and I. Engels. 1987. Antibakterielle Aktivität von Sucralfat in künstlichem Magensaft. Intensivmedizin. 24:163-166.
6. Dörner, A., A. Witthohn, and E. Kraas. 1990. Ciprofloxacin prior to colon surgery. Diagn. Microbiol. Infect. Dis. 13:177-179.
7. Drusano, G. L. 1987. An overview of the pharmacology of intravenously administered ciprofloxacin. Am. J. Med. 82:339-345.
8. Edlund, C., L. Lindqvist, and C. E. Nord. 1988. Norfloxacin binds to human fecal material. Antimicrob. Agents Chemother. 32:1869-1874.
9. Esposito, S., D. Barba, G. B. Galante, and O. Laghezza. 1988. Changes in intestinal microflora and treatment of portal systemic encephalopathy. Rev. Infect. Dis. 10:197.
10. Folkman, J., S. Szabo, M. Stovroff, P. Mcneil, W. Li, and Y. Shing. 1991. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Surg. 214:414-427.
11. Garrelts, J. C., P. J. Godley, J. D. Peterie, E. H. Gerlach, and C. C. Yakshe. 1990. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob. Agents Chemother. 34:931-933.
12. Griffiths, N. M., B. H. Hirst, and N. L. Simmons. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269:496-502.
13. Hollander, D., and A. Tarnawski. 1990. The protective and therapeutic mechanisms of sucralfate. Scand. J. Gastroenterol. 25:1-5.
14. Holt, H. A., D. A. Lewis, L. O. White, S. Y. Bastable, and D. S. Reeves. 1986. Effect of oral ciprofloxacin on the fecal flora of healthy volunteers. Eur. J. Clin. Microbiol. Infect. Dis. 5:201-205.
15. Jaehde, U., F. Sörgel, A. Reiter, G. Sigl, K. G. Naber, and W. Schunack. 1995. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. 58:532-541.
16. Kappstein, I., and I. Engels. 1987. Antibacterial activity of sucralfate and bismuth subsalicylate in simulated gastric fluid. Eur. J. Clin. Microbiol. Infect. Dis. 6:216-217.
17. LeBel, M. 1988. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 8:3-33.
18. Lehto, P., and K. T. Kivistö. 1994. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob. Agents Chemother. 38:248-251.
19. Lubowski, T. J., C. H. Nightingale, K. Sweeney, and R. Quintiliani. 1992. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. Antimicrob. Agents Chemother. 36:2758-2760.
20. Nix, D. E., W. A. Watson, L. Handy, R. W. Frost, D. L. Rescott, and H. R. Goldstein. 1989. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy 9:377-380.
21. Parpia, S. H., D. E. Nix, L. G. Hejmanowski, H. R. Goldstein, J. H. Wilton, and J. J. Schentag. 1989. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob. Agents Chemother. 33:99-102.
22. Pecquet, S., S. Ravoire, and A. Andremont. 1990. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J. Antimicrob. Chemother. 26:125-129.
23. Ramon, J., S. Dautrey, R. Farinoti, C. Carbon, and E. Rubinstein. 1994. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 38:757-760.
24. Robertson, J. A., I. B. Salusky, W. G. Goodman, K. C. Norris, and J. W. Coburn. 1989. Sucralfate, intestinal aluminum absorption, and aluminium toxicity in a patient on dialysis. Ann. Intern. Med. 111:179-181.
25. Rohwedder, R. W., T. Bergan, S. B. Thorsteinsson, and H. Scholl. 1990. Transintestinal elimination of ciprofloxacin. Diagn. Microbiol. Infect. Dis. 13:127-133.
26. Rozenberg-Arska, M., A. W. Dekker, and J. Verhoef. 1985. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J. Infect. Dis. 152:104-107.
27. Rubinstein, E., S. Dautrey, R. Farinoti, L. St. Julien, J. Ramon, and C. Carbon. 1995. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob. Agents Chemother. 39:99-102.
28. Rubinstein, E., L. St. Julien, J. Ramon, S. Dautrey, R. Farinoti, J.-F. Huneau, and C. Carbon. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169:218-221.
29. Ruckdeschel, G., G. Vogler, K. Unertl, W. Ehret, and H. Scholl. 1989. The effect of intravenous application of ciprofloxacin on the intestinal flora of healthy volunteers. Abstract, p. 2311-2312. In Proceedings of the 16th International Conference on Chemotherapy, Jerusalem.
30. Scholl, H., K. Schmidt, and B. Weber. 1987. Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. J. Chromatogr. 416:321-330.
31. Sörgel, F., K. G. Naber, U. Jaehde, A. Reiter, R. Seelman, and G. Sigl. 1989. Brief report: gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am. J. Med. 87(5A): 62-65.
32. Staib, A. H., D. Beermann, S. Harder, U. Fuhr, and D. Liermann. 1989. Absorption differences of ciprofloxacin along the human gastrointestinal tract determined using a remote-control drug delivery device (HF-capsule). Am. J. Med. 87(5A):66-69.
33. Szabo, S. 1991. The mode of action of sucralfate: the I x 1 x 1 mechanism of action. Scand. J. Gastroenterol. 26:7-12.
34. Tanimura, H., S. Tominaga, F. Rai, and H. Matsumoto. 1986. Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. Arzneim.-Forsch. 36:1417-1420.
35. van Saene, J. J. M., H. K. F. van Saene, J. N. Geitz, and C. F. Lerk. 1988. Effects of ciprofloxacin on the intestinal flora. Rev. Infect. Dis. 10:198.
36. van Saene, J. J. M., H. K. F. van Saene, and C. F. Lerk. 1986. Inactivation of quinolones by feces. J. Infect. Dis. 153:999-1000. (Letter.)
37. Vieil, B., B. Krause, K.-H. Vestweber, S. Schaaf, and H. Scholl. 1992. Transintestinal elimination of ciprofloxacin in humans - concomitant assessment of its metabolites in serum, ileum and colon. Infection 20:324-327.
38. Yuk, J. H., C. N. Nightingale, and R. Quintiliani. 1989. Ciprofloxacin levels when receiving sucralfate. JAMA 262:901. (Letter.)
39. Zeiler, H.-J., U. Petersen, W. Gau, and H. J. Ploschke. 1987. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Arzneim.-Forsch. 37:131-134.